InterMune reports positive interim Phase II data for hepatitis C protease inhibitor
This article was originally published in Scrip
InterMune's hepatitis C protease inhibitor danoprevir has achieved better rates of rapid virologic response (RVR) and complete early virologic response (cEVR) than the current standard of care in a Phase IIb study.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.